Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Zacks Small-Cap Research Sets $15 Valuation On Edesa Biotech

Zacks Small-Cap Research Sets $15 Valuation On Edesa Biotech

Zacks_SCR_Research_08242022_EDSA_Bautz.pdf (q4cdn.com)

byBenzinga Newsdesk

August 24, 2022

1 minute read

Zacks_SCR_Research_08242022_EDSA_Bautz.pdf (q4cdn.com)

Here’s How Much $100 Invested In Micron Technology 15 Years Ago Would Be Worth Today

By Benzinga Insights

November 22, 4:02 PM

Micron Technology (NASDAQ:MU) has outperformed the market over the past 15 years by 6.81% on an annualized basis…

Installed Building Products Q4 Adj EPS $2.43 Beats $2.16 Estimate, Sales $686.49M Beat $676.69M Estimate

By Benzinga Newsdesk

February 22, 8:31 AM

Installed Building Products (NYSE:IBP) reported quarterly adj. earnings of $2.43 per share which beat the analyst consensus estimate of $2.16 by 12.5 percent. This is a 71.13 percent increase over earnings of $1.42 per

IBP

Schwazze Reports Q2 2023: Revenue $42.4M Despite Challenges, Adjusted EBITDA $13.8M

By Joana Scopel

August 9, 7:22 PM

Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) reported its financial and operating results Wednesday afternoon for the second quarter that ended June 30, 2023.

SHWZ

NASA Turned Him Down So He Built His Own Billion Dollar Rocket Company

By Adam Eckert

April 14, 9:08 AM

This story is part of a new series of features on the subject of success, Benzinga Inspire.

Zacks Small-Cap Research Sets $15 Valuation On Edesa Biotech

Related Posts

Here’s How Much $100 Invested In Micron Technology 15 Years Ago Would Be Worth Today

Installed Building Products Q4 Adj EPS $2.43 Beats $2.16 Estimate, Sales $686.49M Beat $676.69M Estimate

Schwazze Reports Q2 2023: Revenue $42.4M Despite Challenges, Adjusted EBITDA $13.8M

NASA Turned Him Down So He Built His Own Billion Dollar Rocket Company